By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on Stem Cell Research have been published. According to news reporting originating in Seoul, South Korea, by NewsRx journalists, research stated, "Fistula is a representative devastating complication in Crohn's patients due to refractory to conventional therapy and high recurrence. In our phase I clinical trial, adipose tissue-derived stem cells (ASCs) demonstrated their safety and therapeutic potential for healing fistulae associated with Crohn's disease."
The news reporters obtained a quote from the research from Ewha Woman's University, "This study was carried out to evaluate the efficacy and safety of ASCs in patients with Crohn's fistulae. In this phase II study, forty-three patients were treated with ASCs. The amount of ASCs was proportioned to fistula size and fistula tract was filled with ASCs in combination with fibrin glue after intralesional injection of ASCs. Patients without complete closure of fistula at 8 weeks received a second injection of ASCs containing 1.5 times more cells than the first injection. Fistula healing at week 8 after final dose injection and its sustainability for 1-year were evaluated. Healing was defined as a complete closure of external opening without any sign of drainage and inflammation. A modified per-protocol analysis showed that complete fistula healing was observed in 27/33 patients (82%) by 8 weeks after ASC injection. Of 27 patients with fistula healing, 26 patients completed additional observation study for 1-year and 23 patients (88%) sustained complete closure. There were no adverse events related to ASC administration. ASC treatment for patients with Crohn's fistulae was well tolerated, with a favorable therapeutic outcome. Furthermore, complete closure was well sustained."
According to the news reporters, the research concluded: "These results strongly suggest that autologous ASC could be a novel treatment option for the Crohn's fistula with high-risk of recurrence."
For more information on this research see: Autologous Adipose Tissue-Derived Stem Cells Treatment Demonstrated Favorable and Sustainable Therapeutic Effect for Crohn's Fistula. Stem Cells, 2013;31(11):2575-2581. Stem Cells can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Stem Cells - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1549-4918)
Our news correspondents report that additional information may be obtained by contacting W.Y. Lee, Ewha Woman's University, Center Cell Signaling & Drug Discovery Res, Coll Pharm, Seoul, South Korea. Additional authors for this research include K.J. Park, Y.B. Cho, S.N. Yoon, K.H. Song, D.S. Kim, S.H. Jung, M. Kim, H.W. Yoo, I. Kim, H. Ha and C.S. Yu (see also Stem Cell Research).
Keywords for this news article include: Asia, Tissue Engineering, Biomedical Engineering, Biomedicine, Seoul, Therapy, Treatment, South Korea, Bioengineering, Fibrin Sealant, Medical Devices, Stem Cell Research, Adverse Drug Reaction, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC